H.C. Wainwright lowered the firm’s price target on Karyopharm (KPTI) to $7 from $56 and keeps a Buy rating on the shares. The firm updated its model for the reverse stock split.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm trading halted, news pending
- Karyopharm implementing 1-for-15 reverse stock split
- Karyopharm Therapeutics: Hold Rating Maintained Amid Revenue Stagnation and Competitive Pressures
- Karyopharm’s Earnings Call: Growth Amid Financial Challenges
- Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating